Kalaris Therapeutics (KLRS) Tops Q2 EPS by 2c

Kalaris Therapeutics (NASDAQ: KLRS) reported Q2 EPS of ($0.48), $0.02 better than the analyst estimate of ($0.50).

For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.

You May Also Be Interested In

• Microsoft plans data center push to triple its computing power - Bloomberg
• Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance
• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance